Clinical Trials Search

Department: Cardiology
Diagnosis: Cardiac - Arrhythmia
Sponsor: Janssen
Indentifier #: NCT01877915
Title: A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure COMMANDER HF Study
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Sub-Investigator(s):
  • Kondareddy M.D., Shreekanth R.
  • Rudzinski M.D., Wojciech
Sponsor: Pfizer
Indentifier #: NCT01975389
Title: B1481038 PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-04950615, IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Sub-Investigator(s):
  • Kondareddy M.D., Shreekanth R.
  • Rudzinski M.D., Wojciech
Sponsor: Pfizer
Indentifier #: NCT01975376
Title: B1481022: Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Pf-04950615, In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Sub-Investigator(s):
  • Kondareddy M.D., Shreekanth R.
  • Rudzinski M.D., Wojciech
Sponsor: Pfizer
Indentifier #: NCT01968967
Title: B1481020, A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, LONG-TERM SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS – SPIRE LDL